Your browser is no longer supported. Please, upgrade your browser.
ZYME Zymeworks Inc. daily Stock Chart
Zymeworks Inc.
Index- P/E- EPS (ttm)-0.52 Insider Own47.42% Shs Outstand24.81M Perf Week-1.40%
Market Cap297.22M Forward P/E- EPS next Y-2.32 Insider Trans- Shs Float13.39M Perf Month-3.39%
Income-10.40M PEG- EPS next Q-0.68 Inst Own22.20% Short Float0.37% Perf Quarter16.59%
Sales51.80M P/S5.74 EPS this Y81.60% Inst Trans-0.11% Short Ratio1.85 Perf Half Y32.96%
Book/sh4.58 P/B2.62 EPS next Y23.30% ROA-9.80% Target Price16.20 Perf Year-
Cash/sh3.54 P/C3.39 EPS next 5Y- ROE-14.50% 52W Range6.25 - 14.25 Perf YTD57.77%
Dividend- P/FCF- EPS past 5Y- ROI-10.80% 52W High-15.93% Beta-
Dividend %- Quick Ratio6.30 Sales past 5Y- Gross Margin- 52W Low91.68% ATR0.56
Employees147 Current Ratio6.30 Sales Q/Q2143.30% Oper. Margin-23.50% RSI (14)52.98 Volatility3.31% 5.28%
OptionableNo Debt/Eq0.00 EPS Q/Q249.90% Profit Margin-20.10% Rel Volume0.18 Prev Close12.02
ShortableYes LT Debt/Eq0.00 EarningsMar 21 AMC Payout- Avg Volume26.66K Price11.98
Recom1.60 SMA201.36% SMA506.85% SMA20031.26% Volume4,726 Change-0.29%
Mar-19-18Initiated Raymond James Outperform
Apr-17-18 05:00AM  Zymeworks Presents Preclinical Data at the Annual Meeting of the American Association for Cancer Research Business Wire
Apr-03-18 11:39AM  Was Zymeworks Incs (TSE:ZYME) Earnings Growth Better Than The Industrys? Simply Wall St. -7.79%
Mar-14-18 04:05PM  Zymeworks Reports 2017 Year-End Financial Results Business Wire
04:05PM  Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition Business Wire
Mar-07-18 04:05PM  Zymeworks to Present at Barclays 2018 Global Healthcare Conference Business Wire
Feb-28-18 04:05PM  Zymeworks Opening Clinical Sites in Canada Business Wire
Jan-07-18 07:00PM  Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities Business Wire
Dec-28-17 03:29PM  Lifshitz & Miller LLP Announces Investigation of Alon USA Partners, LP, Amplify Snack Brands, Inc., Kindred Healthcare, Inc., Pinnacle Entertainment, Inc., Regal Entertainment Group, Sigma Designs, Inc. and Zymeworks Inc. PR Newswire
Dec-20-17 10:03PM  ZYME INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Zymeworks Inc. Investors Business Wire
Dec-15-17 06:46AM  Zymeworks (ZYME) Alert: Johnson Fistel Announces Investigation of Zymeworks Inc.; Encourages Investors to Contact the Firm for Additional Information PR Newswire -6.27%
Dec-05-17 05:00AM  Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium Business Wire +6.86%
Nov-15-17 07:30AM  Featured Company News - Zymeworks Enters Into License Agreement with Janssen Biotech to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics ACCESSWIRE
Nov-13-17 04:15PM  Zymeworks to Present at Upcoming 2017 Stifel Healthcare Conference Business Wire +24.75%
05:00AM  Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics Business Wire
Nov-08-17 04:15PM  Zymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update Business Wire
Sep-19-17 05:00AM  Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks Azymetric Platform into Preclinical Development Business Wire
Sep-11-17 07:15AM  Zymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress (ESMO) Business Wire
Sep-07-17 01:59PM  2 Names Barclays Is Now Bearish On In Biotech Benzinga -6.89%
Sep-06-17 05:00AM  Zymeworks to Present at the European Society for Medical Oncology 2017 Congress and Hold Webcast to Review Clinical Results Business Wire
Aug-29-17 05:00AM  Zymeworks to Participate in Upcoming Healthcare and Biotech Conferences Business Wire +7.71%
Aug-08-17 04:01PM  Zymeworks Reports Second Quarter 2017 Financial Results Business Wire
Aug-04-17 04:05PM  Zymeworks to Present at 37th Annual Canaccord Genuity Growth Conference Business Wire
Aug-03-17 05:00AM  Zymeworks Appoints Dr. Natalie Sacks to its Board of Directors Business Wire
Aug-01-17 04:30PM  Zymeworks to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017 Business Wire
Jul-18-17 05:00AM  Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration Business Wire
Jun-12-17 07:00AM  Drug Candidates Developed Using Zymeworks Azymetric Platform Nominated for Late-Stage, Preclinical Development by Lilly Business Wire
Jun-04-17 09:00AM  Zymeworks Presents Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the American Society of Clinical Oncology Annual Meeting (ASCO 2017) Business Wire
May-26-17 07:59AM  Zymeworks Announces Partial Exercise of Over-Allotment Option for its Initial Public Offering Business Wire
May-23-17 02:09PM  Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst Benzinga
May-17-17 05:00PM  Zymeworks to Present at the 2017 American Society of Clinical Oncology Annual Meeting Business Wire
May-15-17 04:01PM  Zymeworks Reports First Quarter 2017 Financial Results Business Wire
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.